Company Analysis
Sign in

ADC Therapeutics SA (ADCT)

NYSE: ADCT · Pharmaceutical Preparations · Epalinges, CH · filing with the SEC since 2019
Full chart Alerts Compare
Grade5.3
◀ Past 5.5● Present 4.8▶ Future 6.0
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of ADC Therapeutics SA

Nine metrics read from its own filings, by tense
Headline grade
5.3/10
◀ Past5.530% of the headline
● Present4.840% of the headline
▶ Future6.030% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

5.5/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
8.2/10

Has it survived what it has been through?

No warning events in its filings since 2019.

weight 33% of this tense · 82nd percentile among 497 sector filers · read for itself

From the record

ADC Therapeutics SA's filings since 2019 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
3.6/10

What has it actually done, year after year?

-27.1% a year over 4 filed years; profitable in 0 of 4.

weight 45% of this tense · 36th percentile among 323 sector filers · read for its customers

From the record

ADC Therapeutics SA's 4 filed years say what it did: revenue went from $210 million in fiscal 2022 to $81 million in fiscal 2025, down 27.1% a year; it rose in 2 of 3 years; the deepest fall was 67% from fiscal 2022 to fiscal 2023; net income was positive in 0 of 4 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-27.1%bottom 12% of its family
  • the share of years revenue rosetop 41% of its family
  • the share of filed years with a profitbottom 27% of its family
  • the deepest fall from a revenue peak66.9%bottom 46% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
5.3/10

How has it treated the people who own it?

SI estimate 5.3/10, confidence 35 of 100 (one part).

weight 22% of this tense · 53rd percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 47% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: ADC Therapeutics SA's shareholder treatment is put at 5.3 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 47% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

4.8/1040% of the headline grade · 2 of 3 filed, 1 estimated

Financial health

as filed
3.2/10

Is it financially healthy right now?

Leverage 158%: owes 158¢ per asset dollar.

weight 45% of this tense · 32nd percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, ADC Therapeutics SA's shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 23 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 158 cents per dollar of assets, and net share issuance: its share count grew 30.8% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 5% of its family
  • gross profit against assetstop 50% of its family
  • the share count against the year beforebottom 41% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
4.3/10

How strong is its position in its industry?

bottom 43% of 315 in its family; net margin -175.3%.

weight 33% of this tense · 43rd percentile among 315 sector filers · read for its customers

From the record

ADC Therapeutics SA's standing among 315 graded names in its industry family: revenue of $81 million in fiscal 2025 ranks in the top 37% by size; a net margin of -175.3% ranks in the bottom 48%; revenue growth of -27.1% a year over the last 3 filed years ranks in the bottom 18% (its annual reports).

What it rests on

  • revenue against the family$81.4Mtop 37% of its family
  • net margin-175.3%bottom 48% of its family
  • three-year revenue growth-27.1%bottom 18% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

SI estimate
8.7/10

What are the people in charge doing?

SI estimate 8.7/10, confidence 35 of 100 (one part).

weight 22% of this tense · 87th percentile among 415 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 13% of 415 in its family; the record of its people begins on 2024-01-02 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.9 years and cannot see past it; a floor under five years is not read as years in charge.
What the record cannot read
The record of its people begins on 2024-01-02 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.9 years and cannot see past it; a floor under five years is not read as years in charge.
How it was reasoned
one part: officer and director changes on Form 8-K, against the people in charge, the one part on file, ranked among 415 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: ADC Therapeutics SA's leadership is put at 8.7 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 13% of 415 in its family; the record of its people begins on 2024-01-02 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.9 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.

▶ Future

What are they set up to do next?

6.0/1030% of the headline grade · 3 of 3 filed

Room to expand

as filed
6.7/10

How much room does it have to grow?

top 33% of 273 in its family for room to expand.

weight 45% of this tense · 67th percentile among 273 sector filers · read for itself

From the record

ADC Therapeutics SA's room to grow, from the newest filed statements (fiscal 2025): cash of $261 million against no long-term debt tagged leaves 80.9% of its assets as net cash, top 18% of its family; cash from operations less capital spending is -173.8% of revenue (bottom 44%); a gross margin of 92.9% (top 10%); research spending of 127.8% of revenue (top 48%) (its annual report).

What it rests on

  • cash less debt against assets80.9%top 18% of its family
  • cash from operations less capital spending against revenue-173.8%bottom 44% of its family
  • gross margin92.9%top 10% of its family
  • research spending against revenue127.8%top 48% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
4.5/10

What could actually drive growth from here?

bottom 45% of 306 in its family for growth drivers.

weight 33% of this tense · 45th percentile among 306 sector filers · read for its customers

From the record

ADC Therapeutics SA's growth drivers, from the filed years to fiscal 2025: revenue grew -27.1% a year over the last three filed years against -27.1% over all 4, speeding up (top 40% of its family); the newest year grew 14.9% (top 42%); research spending grew -17.7% a year (bottom 21%); capital spending grew -27.3% a year (bottom 39%) (its annual reports). ADC Therapeutics SA reported 3 product lines in fiscal 2025: Product at $74 million (90%), License Revenues at $5 million (6%), Royalty Revenue at $3 million (3%); 2 of 2 grew against the year before (its annual report).

What it rests on

  • three-year growth against the whole span+0.0 points a yeartop 40% of its family
  • the newest year's revenue growth14.9%top 42% of its family
  • three-year growth of research spending-17.7%bottom 21% of its family
  • three-year growth of capital spending-27.3%bottom 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
6.6/10

Did its newest year beat what its own record pointed to?

top 34% of 233 in its family for expectations against reality.

weight 22% of this tense · 66th percentile among 233 sector filers · read for its shareholders

From the record

ADC Therapeutics SA's newest year against its own record: revenue of $81 million in fiscal 2025 came in 97.6% above the $41 million its prior three years' pace pointed to (top 16% of its family); net income of $143 million against a prior three-year average of $185 million (top 46%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 39%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace97.6%top 16% of its family
  • net income against the prior three years' average+23%top 46% of its family
  • net margin against its prior average+39.0 pointstop 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton ADCT · research, not advice